Return to Trial Database

HCRN-GI18-333

Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL)

Status

Currently Enrolling

Cancer Type(s)

Gastric Gastroesophageal Junction

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-GI18-333 being conducted in.

Froedtert & the Medical College of Wisconsin